A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients

Status unconfirmed

Conditions studied: Mild Cognitive Impairment

In brief

This retrospective analysis of de-identified data from 700 charts of consecutive patients from this patient population is to investigate the prevalence of hyperhomocysteinemia and associated metabolic abnormalities in this naturalistic grouping of patients with various stages of cognitive loss and diagnosed with various types of dementia.

Key facts

Study ID

NCT01594541

Run by

Pamlab, Inc.

People needed

700

Starts

2013-01-01

Expected to finish

2014-04-01

Last updated by the study team

2014-03-24

Who can join

Age: 55 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals between the ages of 55 and 89 years old
• Meeting criteria for Mild Cognitive Impairment or dementia with a minimum MOST score of 5 but not over 23
• Has a minimum of 3 months evaluation
• Able to undergo testing for cognition and complete the GDS

You may not qualify if…

• Known allergy/intolerance to any ingredient in Cerefolin NAC®
• Substantial impediments to adherence, such as severe dementia without caregiver to administer medication
• Inability to swallow pill-form medication
• Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease
• Hcy score lower than 11

Where it is running

• Clionsky Neuro Systems, Inc. — Springfield, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.